Targeting Drug Costs Will Have Minimal Impact On Federal Health Care Spending - Avalere
This article was originally published in The Pink Sheet Daily
Executive Summary
Recent analysis shows that only about 8% of federal Medicare and Medicaid spending goes to brand-name prescription drugs.
You may also be interested in...
Obama Deficit Reduction Plan Takes Aim At Drug Costs, Strengthens IPAB
President Obama's deficit reduction framework borrows ideas from previous spending documents such as the 2012 budget and the fiscal commission report in its cost-cutting recommendations for Medicare.
Three Ways IPAB Can Reduce Drug Costs In Medicare: An Interview With Scott Gottlieb
The Independent Payment Advisory Board is likely to take three approaches to reining in drug costs under Medicare, according to American Enterprise Institute Resident Fellow Scott Gottlieb.
Medicare "Least Costly Alternative" Nixed By Courts, But Could Reform Bill's IMAB Convey New Authority?
A federal appeals court has upheld a lower court's determination that Medicare statutes do not allow the program to limit reimbursement for a drug under Part B to the rate for a "least costly alternative" drug